# David D. Stenehjem

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-d-stenehjem/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,848 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 23 |
| i10-index | 47 |
| Last Known Institution | University of Minnesota |
| OpenAlex ID | https://openalex.org/A5024053204 |
| ORCID iD | 0000-0002-1831-285X |
| Works | 244 |

## Researcher papers

- [American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer](https://scholariq.org/papers/american-society-of-hematology-2021-guidelines-for-management-of-venous/)
- [Diagnosis and treatment of cancer‐related anemia](https://scholariq.org/papers/diagnosis-and-treatment-of-cancer-related-anemia/)
- [PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer](https://scholariq.org/papers/pd1-pdl1-inhibitors-for-the-treatment-of-advanced-urothelial-bladder-cancer/)
- [Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer](https://scholariq.org/papers/real-world-outcomes-of-immunotherapy-based-regimens-in-first-line-advanced-non/)
- [Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy](https://scholariq.org/papers/circulating-immune-cell-phenotype-dynamics-reflect-the-strength-of-tumor-immune/)
- [Tumor mutational burden in lung cancer: a systematic literature review](https://scholariq.org/papers/tumor-mutational-burden-in-lung-cancer-a-systematic-literature-review/)
- [Novel and Emerging Strategies in Drug Delivery for Overcoming the Blood–Brain Barrier](https://scholariq.org/papers/novel-and-emerging-strategies-in-drug-delivery-for-overcoming-the-blood-brain/)
- [Competitive Inhibition of Organic Anion Transporting Polypeptide 1c1-Mediated Thyroxine Transport by the Fenamate Class of Nonsteroidal Antiinflammatory Drugs](https://scholariq.org/papers/competitive-inhibition-of-organic-anion-transporting-polypeptide-1c1-mediated/)
- [Neutrophil-lymphocyte ratio as a predictive biomarker for response to high dose interleukin-2 in patients with renal cell carcinoma](https://scholariq.org/papers/neutrophil-lymphocyte-ratio-as-a-predictive-biomarker-for-response-to-high-dose/)
- [Panobinostat for the treatment of multiple myeloma: the evidence to date](https://scholariq.org/papers/panobinostat-for-the-treatment-of-multiple-myeloma-the-evidence-to-date/)
- [Total Dose Iron Dextran Infusion in Cancer Patients: Is it SaFe<sup>2+</sup>?](https://scholariq.org/papers/total-dose-iron-dextran-infusion-in-cancer-patients-is-it-safe-sup-2-sup/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Economic and Financial Impacts of Cancer](https://scholariq.org/topics/economic-and-financial-impacts-of-cancer/)
- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [University of Minnesota](https://scholariq.org/institutions/university-of-minnesota/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.